In vascular endothelial cells, cytokines induce genes that are expressed in inflammatory lesions partly through the activation of transcription factor NF-κB (nuclear factor-κB). Among the members of the NF-κB/rel protein family, homodimers of the RelA subunit of NF-κB can also function as strong transactivators when expressed in cells. However, the functional role of endogenous RelA homodimers has not been clearly elucidated. We investigated whether RelA homodimers are induced in cytokine-treated vascular endothelial cells. Gel mobility-shift and supershift assays revealed that a cytokine TNFα (tumour necrosis factor α) activated both NF-κB1/RelA heterodimers and RelA homodimers that bound to a canonical κB sequence, IgκB (immunoglobulin κB), in SV40 (simian virus 40) immortalized HMEC-1 (human dermal microvascular endothelial cell line 1). In HMEC-1 and HUVEC (human umbilical-vein endothelial cells), TNFα also induced RelA homodimers that bound to the sequence 65-2κB, which specifically binds to RelA homodimers but not to NF-κB1/ RelA heterodimers in vitro. Deoxycholic acid, a detergent that can dissociate the NF-κB-IκB complex (where IκB stands for inhibitory κB), induced the binding of the RelA homodimers to 65-2κB from the cytosolic fraction of resting HMEC-1. Furthermore, TNFα induced the transcriptional activity of a reporter gene that was driven by 65-2κB in HMEC-1. These results suggest that in addition to NF-κB1/RelA heterodimers, TNFα also induces RelA homodimers that are functionally active. Thus RelA homodimers may actively participate in cytokine regulation of gene expression in human vascular endothelial cells.
INTRODUCTION
In a variety of cell types, cytokines regulate the expression of many viral and cellular genes through the transcriptional factor NF-κB (nuclear factor κB) (reviewed in [1] [2] [3] ). NF-κB was first described as a heterodimer that consists of NF-κB1 and RelA subunits [4] [5] [6] . As an inactive form, NF-κB is present in complex with its inhibitory protein IκB (inhibitory κB) in the cytosol of cells. Cytokines and other inducers activate NF-κB by releasing it from IκB [3, 7] . This process depends on the degradation of IκB and is inhibited by the antioxidant PDTC (pyrrolidine dithiocarbamate) [8] [9] [10] [11] . The inhibition of NF-κB activation by the antioxidant suggests that reactive oxygen species play an essential role in the immediate early response of cells [12] .
In vascular endothelial cells, NF-κB activates the expression of genes involved in immune and inflammatory diseases, such as cytokines, IL-6 (interleukin-6) and IL-8 [13] [14] [15] . It also activates genes coding for adhesion molecules, VCAM-1 (vascular cell adhesion molecule-1) [16, 17] , E-selectin [18] [19] [20] and ICAM-1 (intercellular adhesion molecule-1) [21, 22] . These genes are regulated by binding of NF-κB to the consensus κB motifs, albeit with some differences in the nucleotide sequences present in their promoters. We reported previously that PDTC selectively suppresses the induction of VCAM-1 expression by cytokines, but not that of E-selectin or ICAM-1, in endothelial cells [23] . These results suggest that oxidative stress differentially regulates these genes and raises questions of whether and to what degree vascular endothelial cells utilize NF-κB (NF-κB1/RelA heterodimer) or other NF-κB-like molecules to regulate these genes selectively.
NF-κB is a member of NF-κB/rel family of transcriptional proteins [1] [2] [3] . Members of this family share the homology of 300 amino acids at N-terminal, which is essential for dimerization and DNA binding, with the proto-oncogene product c-rel and Drosophila morphogen dorsal [1] [2] [3] . Five cDNA of NF-κB/rel family have been cloned, including NF-κB1/p110 [24] [25] [26] [27] , NF-κB2/p100 [27, 28] , RelA [29, 30] , c-rel [31] and RelB [32] . Among these, NF-κB (NF-κB1/RelA heterodimer) has been extensively studied as a potent transcriptional factor. In addition, recent in vitro studies suggest that most of these members can homoor heterodimerize with each other and positively or negatively affect transactivation of κB-controlled genes [2, 29, [33] [34] [35] [36] . There is increasing evidence that the RelA homodimer is a potent transactivator for κB-controlled reporter genes by transient transfection assays, although the activation of RelA homodimer has not been extensively studied in vivo [29, [33] [34] [35] [36] .
Recently, Narayanan et al. [37] reported that the antisense oligonucleotide against mRNA of RelA subunit, but not that against NF-κB1 subunit, inhibits adhesion of a variety of cells including primary cultured endothelial cells. These results suggest that RelA plays an essential role in endothelial cell adhesion. In T-cell line Jurkart, the cytokine IL-8, which is also produced in endothelial cells, was shown to utilize the RelA-homodimer-like protein to drive the promoter activity through the κB consensus site [38] . Based on these studies, one can speculate that in endothelial cells the RelA homodimer or homodimer-like protein may actively participate in gene regulation.
Recently, Kunsch et al. [39] characterized κB sequences that specifically bind to RelA homodimer but not to NF-κB1 homodimer or to NF-κB (NF-κB1/RelA heterodimer). These sequences were isolated from a pool of randomly prepared κB sequences using purified RelA protein as a probe [39] . This in vitro result prompted us to examine the possible involvement of RelA homodimer in cytokine-treated vascular endothelial cells with the RelA homodimer-specific sequence.
In the present study, we examined whether RelA homodimers were induced in cytokine-treated endothelial cells, HMEC-1 (human dermal microvascular endothelial cell line 1) and HUVEC (human umbilical-vein endothelial cells). With a canonical κB sequence, IgκB (immunoglobulin κB), and a RelA homodimer-specific sequence, 65-2κB, as probes, we performed gel mobility and supershift assays using antibodies raised against members of the NF-κB/rel protein family. The results showed that in addition to NF-κB (NF-κB1/RelA heterodimers), TNFα (tumour necrosis factor α) also induced RelA homodimers in the vascular endothelial cells. Dissociation of cytosolic protein complexes with DOC (deoxycholic acid) suggested that, like NF-κB1/ RelA heterodimers, the nuclear translocation of RelA homodimers is also regulated. Importantly, in HMEC-1, TNFα induced the transcriptional activity of a reporter gene that was driven by the RelA homodimer specific enhancer element. Thus homodimers of RelA may also participate in TNFα regulation of NF-κBdependent gene expression in endothelial cells.
EXPERIMENTAL

Cell culture
HMEC-1 was immortalized with SV40 (simian virus 40) large T-antigen [40] . The established cell line, immortalized human dermal microvascular endothelial cells, termed CDC/EC, was generously provided by E.W. Ades (Centers for Disease Control, Atlanta, GA, U.S.A.) and maintained in EBM medium obtained from Clonetics (San Diego, CA, U.S.A.) supplemented with 15 % (v/v) FBS (fetal bovine serum; Atlanta Biological, Norcross, GA, U.S.A.), 10 ng/ml epidermal growth factor (Intergen, Purchase, NY, U.S.A.), and 1 µg/ml cortisol (Sigma, St. Louis, MO, U.S.A.). HUVEC were purchased from Clonetics and were cultured in M199 medium (Gibco BRL, Gaithersburg, MD, U.S.A.) supplemented with 20 % FBS, 16 units/ml heparin (ESI Pharmaceuticals, Cherry Hill, NJ, U.S.A.), 50 mg/ml endothelial cell growth supplement (Collaborative Research, Bedford, MA, U.S.A.) and 25 mM Hepes buffer. Both cell types were cultured in a humidified atmosphere of 5 % CO 2 in air. The medium for both cell types contained 2 mM L-glutamine, 100 units/ml penicillin and 100 mg/ml streptomycin. HUVEC were grown on tissue culture plates coated with 0.1 % gelatin and were used within the first six passages. Human recombinant TNFα was obtained from Boehringer Mannheim (Indianapolis, IN, U.S.A.). All other chemicals were of reagent grade.
Nuclear extract and gel mobility-shift assays
Confluent HMEC-1 was exposed to TNFα (100 units/ml) for 1 h, and nuclear proteins were purified by a modification of the method of Dignam et al. [41] . Briefly, after washing with PBS, cells were centrifuged and the cell pellet was suspended in 500 µl of buffer A [10 mM Hepes, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl and 1 mM DTT (dithiothreitol)]. After re-centrifugation, the cells were resuspended in 80 µl of buffer A containing 0.1 % NP40 (Nonidet P40) by gentle pipetting. After incubating for 10 min at 4 • C, the homogenate was centrifuged and the supernatant was stored at − 70 • C as a cytosolic extract. Then the nuclear pellet was washed once with buffer A and resuspended in 50 µl of buffer C (20 mM Hepes, pH 7.9, 25 %, v/v, glycerol, 0.42 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA and 1 mM DTT). This suspension was incubated for 30 min at 4 • C followed by centrifugation at 20 000 g for 10 min. The resulting supernatant was stored at −70 • C as a nuclear extract. Protein concentrations were determined by the Bradford method [42] . To minimize proteolysis, all buffers contained 1.0 mM PMSF, 10 µg/ml antipain, 10 µg/ml leupeptin and 0.023 TIU/ml aprotinin.
The sequences of oligonucleotides used for probes are as follows (κB sequences are underlined) [39] : 65-2κB: 5 -GTACC- The DNA binding reaction was performed at 30 • C for 15 min in a volume of 20 µl, which contained 2 µg of nuclear extract, 225 µg/ml BSA, 100 000 c.p.m. 32 P-labelled probe (∼ 1 ng), 0.1 mg/ml poly(dI-dC) and 15 µl of binding buffer (12 mM Hepes, pH 7.9, 4 mM Tris, 60 mM KCl, 1 mM EDTA, 12 % glycerol, 1 mM DTT and 1 mM PMSF) with or without 100-fold molar excess of unlabelled competitor. Samples were subjected to electrophoresis on native 4 % (w/v) polyacrylamide gels in 1 × Tris/glycine buffer.
For dissociation experiments, 5 µg of cytosolic extract or 2 µg of nuclear extract in binding buffer was treated with 1.0 % DOC followed by 1.2 % (v/v) NP40, and incubated with a radiolabelled probe.
For the supershift assay, the antibody was added to each reaction mixture before adding the radiolabelled probe. The mixture was then incubated for 15 min at room temperature (26 • C). Anti-RelA, c-rel and RelB antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Anti-NF-κB1 antibody and in vitro translated NF-κB1, NF-κB1/RelA and RelA were gifts from C. Kunsch and C. Rosen (Human Genome Sciences, Rockville, MD, U.S.A.).
CAT (chloramphenicol acetyltransferase) assays
At 1 day before transfection, HMEC-1 was split at a ratio to yield 80 % confluence. Transfection was performed by the calcium phosphate co-precipitation technique using 10 µg of reporter plasmids for 18 h. After a 2 h recovery period, cells were either left untreated or treated with TNFα for 20 h. For co-transfection with expression vectors, each expression vector was cotransfected with reporter genes for 40 h. The amount of expression vector is indicated in Figure legends . Promoterless plasmid poLUC [43] was used for adjusting the amount of transfected DNA. Following transfection, cells were harvested and extracts prepared using three rapid freeze-thaw cycles in 0.25 M Tris (pH 8.0). Protein content was determined using the Bradford technique [42] . Same amounts of proteins were assayed for CAT activity according to the method described in [44, 45] . Acetylated and unacetylated forms of chloramphenicol were separated by TLC. Each assay was performed in duplicate and in at least two separate experiments.
Expression vectors and CAT reporter genes
The eukaryotic expression vectors CMV-NF-κB1 (also called p50), CMV-RelA (also called p65) and CMV-NF-κB1/RelA (also called p50/65) contain the respective cDNAs cloned between a CMV (cytomegalovirus) promoter β-globin intron and SV40 poly(A) signal [35] . CMV-NF-κB1/RelA encodes chimaeric protein consisting of a DNA-binding domain of NF-κB1 (amino acids 1-370) and transactivation domain of RelA (amino acids 309-550). The reporter plasmids p(IgκB)4CAT and p(65-2κB)-4CAT contain four tandem copies of the respective κB DNA sequences cloned upstream of the HIV-1 LTR (long terminal repeat) and fused to the coding region of the bacterial CAT gene [39] . These vectors were gifts from C. Kunsch and C. Rosen.
RESULTS
TNF-activated HMEC-1 NF-κB proteins have differential affinity for IgκB and 65-2κB
The canonical NF-κB motif, IgκB (5 -GGGACTTTCC-3 ), present in the enhancer region of immunoglobulin light chain gene and in LTR of HIV has been well characterized to bind to NF-κB (NF-κB1/RelA heterodimer) [46, 47] . By gel mobilityshift assays, IgκB made two complexes with nuclear proteins, fast mobility (F) and slow mobility (S), of TNF-activated HMEC-1 ( Figure 1A , lane 2). The intensity of complex F was severalfold greater intensity than that of complex S. The nuclear proteins from unstimulated cells formed a minor complex that had mobility similar to that of the major complex F ( Figure 1A, lane 1) . The competition studies with unlabelled IgκB (100-fold excess) suggested that the complexes were specific ( Figure 1A Figure 1A , lane 6] competed for the NF-κB complexes. The unlabelled 65-2κB, which specifically binds to RelA homodimers, completely competed for proteins in the complex S and partially for the major complex F. This suggests that 65-2κB has greater affinity for proteins associated with the S complex than those associated with F complex.
We next examined whether TNFα could activate 65-2κBbinding nuclear proteins in HMEC-1. 65-2κB, core sequence 5 -CGGAATTTCC-3 , was isolated from a randomly prepared pool of sequences and was characterized to bind to RelA homodimers and c-rel protein but not to NF-κB1 homodimer or to NF-κB1/RelA heterodimer in vitro [39] . As shown in Figure 1(B) , 65-2κB also formed two complexes, F and S, with the TNFαtreated HMEC-1 nuclear proteins ( Figure 1B, lane 2) . The mobility of these complexes was similar to that formed by IgκB. However, in this situation, the intensity of complex S was severalfold greater than that of complex F, which is the reverse of that observed with IgκB. The control nuclear extract formed a minor complex that had mobility similar to that of complex S, opposite to that observed with IgκB ( Figure 1B, lane 1) . The competition studies with unlabelled 65-2κB (100-fold excess) suggested that both complexes were specific ( Figure 1B, lane 3) . The unlabelled IgκB (100-fold excess) also competed for both Figure 1B, lane 4) . This suggests that the IgκB can also bind to the 65-2κB-binding proteins. Neither the mutated IgκB ( Figure 1B, lane 5) nor the unrelated sequence TRE ( Figure 1B, lane 6) competed for the binding. These studies suggest that the NF-κB complexes F and S bind to both IgκB and 65-2κB but with different affinities.
S and F complexes (
TNFα activates RelA homodimers in addition to NF-κB1/RelA heterodimers in HMEC-1
Both F and S complexes were further characterized by supershift assays using specific polyclonal antibodies raised against NF-κB1, RelA, c-rel and RelB proteins. The complex F formed by IgκB (Figure 2A, lane 1) was completely shifted by Ab-NF-κB1 (where Ab stands for antibody), while the S complex was not affected (Figure 2A, lane 2) . When Ab-RelA was used alone ( These results suggest that IgκB mainly associates with NF-κB1/ RelA heterodimers (complex F), although it can also associate with RelA-or RelA-homodimer-like protein(s) (complex S).
As observed previously, 65-2κB formed a major complex (S) and a minor complex (F) with the nuclear proteins of TNFαtreated HMEC-1 ( Figure 2B, lane 1) . The Ab-NF-κB1 did not shift the S complex ( Figure 2B, lane 2) , while this complex was completely shifted by Ab-RelA ( Figure 2B, lane 3) . When Ab-NF-κB1 and Ab-RelA were used in combination, both S and F complexes were completely shifted ( Figure 2B, lane 4) . Neither Ab-c-rel nor Ab-RelB shifted the complexes F and S ( Figure 2B, lanes 5 and 6) . These results suggest that 65-2κB predominantly associates with RelA-or RelA-homodimer-like proteins (S complex), although it can also associate with NF-κB1/ RelA heterodimers with low affinity.
65-2κB made complexes with in vitro translated RelA and nuclear proteins of TNF-activated HMEC-1 that had the same mobility
As shown in Figure 3 , lane 4, the in vitro translated RelA made a complex with 65-2κB that had mobility similar to that of the complex S formed by the nuclear proteins of TNFα-activated HMEC-1 (lane 5). The in vitro translated NF-κB1 (lane 2) or NF-κB1 + RelA (lane 3) or unprogrammed control (lane 1) did not make any specific complex with 65-2κB. Consistent with previous studies [39] , these results suggest that 65-2κB binds to RelA homodimers and that the homodimers are present in the nuclear extracts of TNF-activated HMEC-1. 
DOC activates RelA homodimers from the cytosolic extract of untreated HMEC-1
NF-κB (NF-κB1/RelA heterodimers) is retained in the cytosol of cells by its inhibitory protein IκB. Cytokines or other activators translocate NF-κB into the nucleus through a mechanism that involves phosphorylation and proteolytic degradation of IκB. DOC can also dissociate NF-κB from IκB that can efficiently bind to κB consensus sequences [1] [2] [3] . Using 65-2κB as a probe, we demonstrate that DOC can also dissociate RelA homodimers from the cytosol of unstimulated HMEC-1 (compare lanes 3 and 4 of Figure 4 ). The mobility of these homodimers was comparable with that obtained through stimulation of HMEC-1 with TNF ( compare lanes 1 and 4) . Figure 4 ). These results suggest that like NF-κB1/RelA heterodimers, RelA homodimers are also retained in the cytosol by IκB or IκBlike proteins and that TNFα activates RelA homodimers through a mechanism similar to that used for NF-κB (NF-κB1/RelA heterodimers).
TNFα induces RelA homodimers in the primary cultures of endothelial cells
As shown in Figure 5 , TNFα also activated 65-2κB-binding proteins in HUVEC (compare lanes 1 and 2) . The binding proteins made a major complex S and a minor complex F. The Ab-RelA shifted both complexes F and S (lane 4), while the Ab-NF-κB1 shifted only the minor complex F without affecting the major complex S. These results suggest that, in addition to NF-κB1/ RelA heterodimers, TNFα also activates RelA or RelA-homodimer-like factors in primary cultured endothelial cells.
TNFα activates the RelA homodimer specific CAT reporter gene in HMEC-1
To determine whether RelA homodimers were transcriptionally active, we performed CAT assays. We used p(65-2κB)4CAT, a CAT reporter gene attached to four tandem repeats of the 65-2κB, to assess the activity of RelA homodimers. As a control, we used p(IgκB)4CAT, a CAT reporter gene attached to four tandem repeats of IgκB. In transfection studies, TNFα increased the activity of p(65-2κB)4CAT severalfold ( Figure 6A, lane 2) above the basal level ( Figure 6A, lane 1) in HMEC-1. Similarly, cotransfection of CMV-RelA, an expression vector encoding the RelA subunit of NF-κB, transactivated the activity of p(65-2κB)4CAT several-fold above the basal level ( Figure 6A, lane 3) . Co-transfection of CMV-NF-κB1/RelA, an expression vector encoding chimaeric protein containing DNA-binding domain of NF-κB1 and the transactivation domain of RelA, a functional mimic of NF-κB1/RelA heterodimers, did not transactivate p(65-2κB)4CAT ( Figure 6A, lane 4) . Under the same conditions, cotransfection of CMV-NF-κB1/RelA into HMEC-1 transactivated p(IgκB)4CAT ( Figure 6B, lane 4) . As expected, both TNFα treatment ( Figure 6B, lane 2) and CMV-RelA co-transfection ( Figure 6B, lane 3) also increased the activity of p(IgκB)4CAT in HMEC-1 ( Figure 6B, lane 1) . These results suggest that the endogenous RelA homodimers present in TNFα-stimulated HMEC-1 is functionally active.
To confirm the functional specificity of the p(65-2κB)4CAT for RelA homodimers, we performed the reconstitution experiment by co-transfecting the reporter gene with a constant amount of CMV-RelA and increasing amounts of CMV-NF-κB1. This method was used to form the NF-κB1/RelA heterodimers in cells and was shown to transactivate p(IgκB)4CAT [33, 36, 48] . As shown in Figure 7 Figure 7C ). Under the same conditions, consistent with previous studies [38, 39] , the RelA transactivation of p(IgκB)4CAT could not be inhibited ( Figure 7B , lanes 3-6). These results suggest that p(65-2κB)4CAT is specifically transactivated by RelA homodimers but not NF-κB1/RelA heterodimers and hence strongly suggest that TNFα activates p(65-2κB)4CAT by inducing RelA homodimers in HMEC-1.
DISCUSSION
We provide evidence that, in addition to NF-κB (NF-κB1/RelA heterodimers), RelA-homodimer-like factors are present in the cytosol of both immortalized and primary vascular endothelial cells. Like NF-κB1/RelA heterodimers, TNFα also stimulates the translocation of RelA-homodimer-like factors to the nucleus. These homodimers were transcriptionally active as judged by the activity of RelA homodimer-driven reporter gene, p(65-2κB)4CAT, in HMEC-1. Our results suggest that in addition to NF-κB1/RelA heterodimers, RelA-homodimer-like factors may also play a significant role in regulating the expression of several genes containing RelA homodimer-specific or canonical κB motif in HUVEC.
Previous studies have shown that the treatment of the cytosolic extract from unstimulated cells with dissociating agent DOC induces the binding of NF-κB (NF-κB1/RelA heterodimers) to IgκB by dissociating the NF-κB-IκB complex [8, 49] . We demonstrate that the treatment of the cytosolic extract from unstimulated endothelial cells with DOC induces the binding of the RelA homodimers to the 65-2κB sequence. This suggests that RelA homodimers are present in the cytosolic fraction of untreated endothelial cells possibly in complex with an inhibitory protein like IκB, which restricts them in the cytoplasm. Consistent with these results, an isoform of IκB, IκBε, has been shown to function predominantly in the cytoplasm to sequester RelA homodimers [50] . Since IκBepsilon is expressed in various cell types, it is possible that this inhibitory protein also retains RelA homodimers in the cytosol of resting endothelial cells.
Using gel mobility-shift assay, we showed both IgκB (5 -GG-GACTTTCC-3) and 65-2κB sequences make two complexes, slow migrating (S) and fast migrating (F), with nuclear proteins of TNFα-treated endothelial cells. The predominant form of the complex formed by IgκB was 'F' and that formed by 65-2κB was 'S'. The S complex was characterized to contain RelA homodimers or an RelA-homodimer-like protein since this complex was supershifted by anti-RelA antibody but not by antibodies against NF-κB1, c-rel or RelB. The involvement of p49/NF-κB2 in the S complex is unlikely because the mobility of NF-κB2/RelA heterodimer is similar to that of NF-κB1/RelA heterodimers, which was characterized to be an F complex [51, 52] . That the complex S contained RelA homodimers was further supported by similar mobility of the complex made by 65-2κB with RelA homodimers prepared from in vitro translated RelA. Importantly, the 65-2κB probe also formed complex S with nuclear proteins of primary cultured HUVEC. This complex was also characterized to contain RelA homodimers. Like NF-κB1/RelA heterodimers, RelA homodimers appeared only after activation of the cells with TNFα. Thus TNFα activates both RelA homodimers as well as NF-κB1/RelA heterodimers in endothelial cells through processing subtypes of IκB that retain these dimers in the cytosol. Recent studies have suggested that RelA homodimers are activated through a mechanism that is distinct from that which activates NF-κB1/RelA heterodimers. ATP stimulation of the cells of macrophage lineage activated solely RelA homodimers, whereas lipopolysaccharide induced prototypical NF-κB/NF-κB1 homodimers and RelA/NF-κB1 heterodimers [53] . It is possible that various stimuli differentially activate RelA homodimers and NF-κB1/RelA heterodimers in endothelial cells, providing basis for the differential regulation of NF-κB-dependent genes. Further studies will determine which stimuli preferentially activate RelA homodimers.
Transient transfection studies revealed that the co-transfection of RelA expression vector that presumably forms RelA homodimers in cells potently activates the κB-controlled reporter gene activity [29, [33] [34] [35] [36] . Our studies suggest that endogenous RelA homodimers could also play a significant role in regulating inflammatory responses in endothelial cells. First, the amount of RelA homodimers activated by TNFα is not less than that of NF-κB1/RelA heterodimers. Secondly, the RelA homodimers were shown to activate transcription through both the canonical κB as well as the RelA homodimer-specific 65-2κB sites. These results are consistent with previous studies which suggest that RelA homodimers can recognize DNA targets consisting of only one cognate half-site containing four base-pairs (5 -GGAA-3 ) and differences in the other half-site provide variations in confirmation and affinity of the complex [54, 55] . Crystal structure of NF-κB1/RelA heterodimer bound to DNA has revealed a 5 bp 5 subsite for NF-κB1, and a 4 bp 3 subsite for RelA. These studies suggest that RelA homodimers could activate transcription through κB consensus sequences that may have weak affinity for NF-κB1/RelA heterodimers.
Co-transfection of NF-κB1 inhibited the RelA-mediated transactivation of 65-2κB-dependent reporter gene probably by making NF-κB1/RelA heterodimers. These studies imply that the presence of NF-κB1/RelA heterodimers could affect the RelA homodimer-mediated transcription.
The 65-2κB was originally characterized as an RelA homodimer-specific sequence [39] . In the present study, however, the 65-2κB sequence also bound to the NF-κB1/RelA heterodimer activated in vivo although with weak affinity. However, the NF-κB1/RelA heterodimer was unable to transactivate a promoter driven by 65-2κB. Although NF-κB1/RelA heterodimers can bind to 65-2κB with weak affinity, they cannot transactivate promoters through these sequences.
Using two different approaches, we demonstrate that a 65-2κBdependent promoter construct, p(65-2κB)4 CAT, is specifically driven by RelA homodimers but not by NF-κB1/RelA heterodimers. In the first approach, co-transfection of the RelA expression vector, CMV-RelA, strongly transactivated p(65-2κB)4CAT, whereas under the same conditions the co-transfection of chimaeric protein NF-κB1/RelA expression vector, CMV-NF-κB1/ RelA, did not. In the second approach, the reconstitution of NF-κB1/RelA heterodimers formed by co-transfection of constant amounts of CMV-RelA and increasing amounts of CMV-NF-κB1 also did not activate the p(65-2κB)4CAT. As observed previously, these results propose the functional specificity of the 65-2κB sequence for RelA homodimer [39] . So, by using p(65-2κB)4 CAT, an RelA homodimer-specific reporter gene, we could conclude that TNFα activates functional RelA homodimers in HMEC-1.
In conclusion, we have demonstrated the functional activation of the RelA homodimers by the cytokine TNFα in HUVEC. This proposes the fascinating possibility that RelA homodimers could participate in inflammatory responses by activating genes containing κB motifs. It would be interesting to find out whether RelA homodimers play any distinct role in endothelial cell apoptosis versus inflammatory response. This work was supported by research grants NIH RO1 HL-66508-01 (to M. A.) and NIH PO1-HL48667 (to R. M. M. and R. Wayne Alexander).
